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Introduction

28
Emerging evidence indicates that melanoma is a very heterogeneous 29 malignancy, with several variants and with multiple signaling pathways contributing to 30 cell proliferation constitutively activated (Herlyn, 2009 ). Therefore, in order to target 31 such diversity, we need to develop combinations of drugs with specific and 32 complementary mechanisms of action (Herlyn, 2009; Ko and Fisher, 2011) . homology and downstream signaling pathways.
10
The fact that both neuronal embryonic progenitor cells and tumor cells have 11 propensity to proliferate and migrate led to the investigation of the role of glutamate and 12 its receptors on the proliferation and migration of cancer cells. It has been reported that 13 GluR subunits are differentially expressed in a variety of tumor cell lines (North et al., proliferation of melanoma cells and to decrease their growth in vivo (Song et al., 2012) .
27
In addition, the AMPAR antagonist CFM-2, as well as the NMDAR antagonists On the other hand, it has been reported that tamoxifen (TAM), a selective 32 estrogen receptor (ER) modulator widely used in the treatment and prevention of breast shown that the coadministration of CYP2D6-inhibiting medication can limit the 9 efficacy of TAM therapy (Kelly et al., 2010) . Therefore, the use of TAM active 10 metabolites may present strong advantages over the utilization of the prodrug, as it 11 would avoid the variability related with TAM metabolism, leading to a more reliable 12 therapeutic outcome.
13
Based on these findings, we investigated the effects of iGluR antagonists on 14 the proliferation of a highly invasive mouse melanoma cell line (K1735-M2). were carried out in triplicate for each independent experiment and the absorbance 5 obtained in control cultures was considered as 100%.
Materials and Methods
7
Cell cycle analysis by flow cytometry 8 The effects of the drugs on cell cycle were monitored by flow cytometry In order to establish the most effective GluR antagonists to pursue our work, 3 we initially studied the effects of the NMDAR channel blockers MK-801 and 4 memantine, and the selective NMDAR competitive antagonist APV, as well as the 5 AMPAR antagonist NBQX, on mouse melanoma K1735-M2 cell biomass by using the 6 SRB assay which correlates with cell number (Fig. 1) . After 72 and 96 h of incubation 7 in the presence of MK-801 and memantine, the cell biomass was decreased and 8 significant effects were detected at 500 μM of MK-801 and at 300 μM of memantine. In 9 contrast, the cell biomass was unaffected by 500 μM of APV or NBQX after 96 h of 10 drug incubation (Fig. 1) . Therefore, in the following experiments we used the NMDAR 11 channel blockers MK-801 and memantine.
12
To elucidate the mechanism underlying the effects of the NMDAR channel (Fig. 4 ).
14 Thus, melanoma cells were subjected to treatment with MK-801 (100 μM) and 15 antiestrogens (5 μM), alone or in combination, over 72 h (Fig. 4) . At this concentration, (Fig. 4) . However, a decrease in the number of viable cells was already observed 31 at 48h when cells were treated with OHTAM (Fig. 5B) , whereas the EDX metabolite 5D-5F).
6
The absence of an increase in the number of dead cells within 72 h of treatment 7 with the drugs was confirmed by the LDH assay (Fig. 6) . Neither the compounds Noteworthy, the combination of MK-801 at 100 μM with the three antiestrogens TAM,
18
OHTAM and EDX significantly decreased BrdU incorporation to 35 %, 9 % and 17 % 19 of control, respectively, which is a much stronger effect relatively to that of the 20 compounds individually (Fig. 7) . Thus, our results showed the combinations of MK-801 21 and the antiestrogens might have a cytostatic effect on melanoma cells, which is more 22 prominent when MK-801 is combined with the TAM metabolites than with the prodrug.
23
To confirm our hypothesis that the rate of proliferation of melanoma cells was effect of the drugs on the cell cycle was analyzed by flow cytometry (Fig. 8) . Untreated 27 cells (control) were characterized by a long and well defined G1 peak, a slightly 28 prominent S phase, a least prominent G2 peak and a relatively low G0/G1 fraction,
29
which was considered as the apoptotic fraction (Fig. 8) . Forty-eight hours after The effects of GluR antagonists on mouse melanoma K1735-M2 cells were 17 assessed by the SRB assay which showed that MK-801 and memantine reduce 18 melanoma cell biomass (Fig. 1) . On the contrary, the AMPAR and KAR antagonist On the other hand, the absence of effect of NBQX suggests that AMPAR and KAR 4 inhibition possibly does not affect melanoma cell viability.
5
The cell viability assay with trypan blue staining revealed that MK-801 and 6 memantine decrease the number of viable cells, without inducing cell death (Fig. 2) .
7
Moreover, the evaluation of LDH activity in the supernatant of melanoma cells (Fig.   8   3A) and the BrdU incorporation assay pointed out that MK-801 and memantine do not 9 induce cancer cell death, but instead they inhibit cell proliferation (Fig. 3B) . Our results, manner when compared with the effect induced by the compounds individually (Fig. 4) . (Fig. 6) , whereas the BrdU incorporation assay pointed out that MK-801 and the 2 antiestrogens inhibit cell proliferation with maximal efficacy when the drugs are used in 3 combination (Fig. 7) . Moreover, the analysis of the cell cycle revealed that the 4 combination of MK-801 with TAM metabolites, OHTAM or EDX, induce cell cycle 5 arrest in G1 (Fig. 8) . These results are in line with other studies that have shown that 6 GluR antagonists co-operate with other cytostatic drugs, such as cyclophosphamide, influence rodents behavior (Gilbert, 1988; Tricklebank, 1989; Kawabe et al., 1998 ) and 7 thus, the MK-801 dose and the duration of treatment necessary to achieve a maximal 8 effect on cancer proliferation without major side effects has yet to be determined.
9
In conclusion, we report that the NMDAR channel blocker MK-801 and 10 antiestrogenic compounds decrease mouse melanoma K1735-M2 cell proliferation and 11 their therapeutic potential may be greatly enhanced when used in combination,
12
particularly with the active metabolites of TAM. 
27
The melanoma cell biomass was evaluated by the SRB assay after 72 h of incubation.
28
Bars represent the mean ± S.E. duplicates. A total of 20 000 events were analyzed for each experiment. ** p<0. x MK-801 and memantine decrease melanoma cell proliferation.
7
x The combination of MK-801 with antiestrogens inhibits melanoma cell 8 proliferation.
9
x These combinations greatly enhance the effects of the compounds 10 individually.
11
x MK-801 combined with tamoxifen active metabolites induces cell cycle 12 arrest in G1.
13
x The combination of MK-801 and antiestrogens is an innovative strategy 14 for melanoma. 
